Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.

BMC Nephrol · 2026 · PMC13151278 · PMID 41904427

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In addition, sibeprenlimab treatment resulted in a greater reduction in 24-hour UPCR among patients using SGLT2i at baseline than among those non-users, even though the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.